AR054220A1 - 5-fenilpirimidinas i sustituidas, composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento - Google Patents
5-fenilpirimidinas i sustituidas, composicion farmaceutica y uso del compuesto para la fabricacion de un medicamentoInfo
- Publication number
- AR054220A1 AR054220A1 AR20060100329A ARP060100329A AR054220A1 AR 054220 A1 AR054220 A1 AR 054220A1 AR 20060100329 A AR20060100329 A AR 20060100329A AR P060100329 A ARP060100329 A AR P060100329A AR 054220 A1 AR054220 A1 AR 054220A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- halogen
- alkyl
- substituted
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004429 atom Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- -1 5-substituted phenylpyrimidines Chemical class 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- IBGCXOFOCKCBNQ-UHFFFAOYSA-N nitro cyanate Chemical group [O-][N+](=O)OC#N IBGCXOFOCKCBNQ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son utiles para usar en terapéutica, en particular en terapéutica o tratamiento de enfermedades cancerosas. Reivindicacion 1: 5-fenilpirimidinas sustituidas caracterizadas porque tienen la formula 1 en donde X es un grupo de la formula NR1R2, OR1a o SR1a, en donde R1, R2, de modo independiente entre sí, designan H, alquilo C1-10, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-10, cicloalquilo C3-8, halocicloalquilo C3-8, fenilo o heteroarilo de 5 o 6 miembros o heterociclilo de 5 o 6 miembros, que contiene 1, 2, 3 o 4 átomos de N o 1, 2 o 3 átomos de N y un átomo de S u O como miembros del anillo, cutos radicales pueden no estar sustituidos o pueden llevar 1, 2, 3 o 4 radicales Ra1; o el radical NR1R2 también puede formar un anillo heterocíclico opcionalmente sustituido de 5 o 6 miembros, que contiene 1, 2, 3 o 4 átomos de N o 1, 2 o 3 átomos de N y un átomo de S u O como miembros del anillo, que son no adyacentes al N de NR1R2, en donde dos átomos de C adyacentes o un átomo de N y un átomo de C adyacente pueden unirse por una cadena alquileno C1-4 y en donde el anillo heterocíclico puede no estar sustituido o puede llevar 1, 2, 3 o 4 radicales Ra1; en donde Ra1 es halogeno, oxo, nitro, ciano, hidroxi, alquilo C1-6, cicloalquilo C3-6, cicloalquenilo C3-6, haloalquilo C1-6, alcoxi C1-6, alquiltio C1-6, -C(=O)-A, -C(=O)-O-A, -C(=O)-N(A')A, C(A')(=N-OA), N(A')A, N(A')-C(=O)-A, N(Aö)-C(=O)-N(A')A, S(=O)m-A, S(=O)m-O-A, S(=O)m-N(A')A, fenilo o heteroarilo de 5 o 6 miembros, que contiene 1, 2, 3, o 4 átomos de N como miembros del anillo o 1, 2, o 3 átomos de N y un átomo de S u O como miembros del anillo, en donde el resto fenilo y el resto hetarilo pueden llevar uno a tres radicales seleccionados del grupo que consiste en halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, halogenalquilo C1-6, alcoxi C1-6, ciano, nitro, -C(=O)-A, -C(=O)-O-A, -C(=O)-N(A')A, C(A')(=NOA) o N(A')A; en donde m es 0, 1 o 2; A, A' y Aö son, de modo independiente entre sí, H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, fenilo, en donde los radicales orgánicos pueden estar parcial o completamente halogenados o pueden estar sustituidos con nitro, cianato, ciano o alcoxi C1-4; o A y A' junto con los átomos a los que están unidos, son un heterociclo saturado, parcialmente insaturado o aromático de 5 o 6 miembros que contiene 1 a 4 heteroátomos del grupo que consiste en O, N y S; R1a tiene uno de los significados dados para R1 salvo para H; Y es un radical seleccionado del grupo que consiste en halogeno, cano, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, alcoxi C1-4, alqueniloxi C3-4, alquiniloxi C3-4, alquiltio C1-6, di-(alquil C1-6)amino o alquil C1-6-amino, en donde los radicales alquilo, alquenilo y alquinilo de Y pueden estar sustituidos con halogeno, ciano, nitro, alcoxi C1-2 o alcoxi C1-4-carbonilo; R4 es un radical diferente de H, que comprende de 1 a 15 átomos que son diferentes de H y que están seleccionados de C, halogeno, N,. O y S, siendo el numero de átomos de C de 0 a 10, siendo el numero de átomos de halogeno de 0 a 5 y siendo el numero de heteroátomos que son diferentes de halogeno de 1 a 4; L es un radical que comprende de a 1 a 10 átomos que son diferentes de H y que están seleccionados de C, halogeno, N, O y S, siendo el numero de átomos de C de 0 a 10, siendo el numero de átomos de halogeno de 0 a 5 y siendo el numero de heteroátomos que son diferentes de halogeno de 0 a 4; n es 0, 1, 2, 3, 4 o 5; y las sales farmacéuticamente aceptables de las 5-fenilpirimidinas sustituidas para usar en terapéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05001955 | 2005-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054220A1 true AR054220A1 (es) | 2007-06-13 |
Family
ID=34933530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060100329A AR054220A1 (es) | 2005-01-31 | 2006-01-30 | 5-fenilpirimidinas i sustituidas, composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080146593A1 (es) |
| EP (1) | EP1845991A2 (es) |
| JP (1) | JP2008528535A (es) |
| KR (1) | KR20070104893A (es) |
| CN (1) | CN101111250A (es) |
| AR (1) | AR054220A1 (es) |
| AU (1) | AU2006208621B2 (es) |
| BR (1) | BRPI0607108A2 (es) |
| CA (1) | CA2595958A1 (es) |
| EA (1) | EA014098B1 (es) |
| IL (1) | IL184375A0 (es) |
| MX (1) | MX2007008397A (es) |
| NZ (1) | NZ556448A (es) |
| PE (1) | PE20061042A1 (es) |
| TW (1) | TW200637556A (es) |
| UA (1) | UA87895C2 (es) |
| UY (1) | UY29352A1 (es) |
| WO (1) | WO2006079556A2 (es) |
| ZA (1) | ZA200707315B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010502674A (ja) * | 2006-09-07 | 2010-01-28 | ノイロサーチ アクティーゼルスカブ | カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体 |
| TW200836741A (en) * | 2007-01-11 | 2008-09-16 | Basf Ag | 2-substituted pyrimidines I in therapy |
| KR100936278B1 (ko) * | 2007-12-14 | 2010-01-13 | 한국생명공학연구원 | 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물 |
| AR072937A1 (es) * | 2008-08-20 | 2010-09-29 | Schering Corp | Derivados de piridina y pirimidina sustituida y su uso en el tratamiento de infecciones virales |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| CN111065635B (zh) * | 2018-01-04 | 2022-07-22 | 无锡安万生物科技有限公司 | 作为mth1抑制剂的新型嘧啶衍生物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4006235A (en) * | 1973-03-23 | 1977-02-01 | Burroughs Wellcome Co. | Treating CNS lymphoma |
| GB8314643D0 (en) * | 1983-05-26 | 1983-06-29 | Wellcome Found | Pyrimidine derivatives |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9700664D0 (en) * | 1997-01-14 | 1997-03-05 | British Tech Group | Anti-cancer agents |
| MXPA03008121A (es) * | 2001-03-15 | 2003-12-12 | Basf Ag | 5-fenilpirimidinas, metodos y productos intermedios para su produccion y uso de las mismas para controlar hongos patogenicos. |
| HRP20031096A2 (en) * | 2001-06-12 | 2005-08-31 | Neurogen Corporation | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
| NZ533265A (en) * | 2001-11-19 | 2006-05-26 | Basf Ag | 5-Phenylpyrimidines, their preparation, compositions comprising them and their use |
| EP1504001B1 (de) * | 2002-02-21 | 2009-04-15 | Basf Se | 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen |
| ATE505462T1 (de) * | 2002-07-22 | 2011-04-15 | Orchid Res Lab Ltd | Neue biologischaktive molekü le |
| US7371758B2 (en) * | 2003-03-13 | 2008-05-13 | National Science & Technology Development Agency | Antimalarial pyrimidine derivatives and methods of making and using them |
| WO2004103978A1 (de) * | 2003-05-20 | 2004-12-02 | Basf Aktiengesellschaft | 2-substituierte pyrimidine |
| JP2006528600A (ja) * | 2003-07-24 | 2006-12-21 | ビーエーエスエフ アクチェンゲゼルシャフト | ２−置換ピリミジン |
| MXPA06003207A (es) * | 2003-09-24 | 2006-06-23 | Wyeth Corp | 5-arilpirimidinas como agentes anti-cancer. |
| US20050070712A1 (en) * | 2003-09-26 | 2005-03-31 | Christi Kosogof | Pyrimidine derivatives as ghrelin receptor modulators |
| DE102004003493A1 (de) * | 2004-01-23 | 2005-08-11 | Bayer Cropscience Ag | 5-Phenylpyrimidine |
| WO2006005571A1 (de) * | 2004-07-14 | 2006-01-19 | Basf Aktiengesellschaft | 2-substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen |
-
2006
- 2006-01-27 TW TW095103598A patent/TW200637556A/zh unknown
- 2006-01-30 CN CNA2006800035983A patent/CN101111250A/zh active Pending
- 2006-01-30 NZ NZ556448A patent/NZ556448A/en not_active IP Right Cessation
- 2006-01-30 JP JP2007552589A patent/JP2008528535A/ja active Pending
- 2006-01-30 AR AR20060100329A patent/AR054220A1/es unknown
- 2006-01-30 PE PE2006000121A patent/PE20061042A1/es not_active Application Discontinuation
- 2006-01-30 US US11/815,042 patent/US20080146593A1/en not_active Abandoned
- 2006-01-30 UA UAA200709766A patent/UA87895C2/ru unknown
- 2006-01-30 AU AU2006208621A patent/AU2006208621B2/en not_active Ceased
- 2006-01-30 EA EA200701582A patent/EA014098B1/ru not_active IP Right Cessation
- 2006-01-30 BR BRPI0607108-2A patent/BRPI0607108A2/pt not_active IP Right Cessation
- 2006-01-30 MX MX2007008397A patent/MX2007008397A/es not_active Application Discontinuation
- 2006-01-30 WO PCT/EP2006/000774 patent/WO2006079556A2/en not_active Ceased
- 2006-01-30 CA CA002595958A patent/CA2595958A1/en not_active Abandoned
- 2006-01-30 EP EP06706482A patent/EP1845991A2/en not_active Withdrawn
- 2006-01-30 KR KR1020077017631A patent/KR20070104893A/ko not_active Ceased
- 2006-01-31 UY UY29352A patent/UY29352A1/es unknown
-
2007
- 2007-07-03 IL IL184375A patent/IL184375A0/en unknown
- 2007-08-29 ZA ZA200707315A patent/ZA200707315B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA014098B1 (ru) | 2010-08-30 |
| JP2008528535A (ja) | 2008-07-31 |
| US20080146593A1 (en) | 2008-06-19 |
| UA87895C2 (en) | 2009-08-25 |
| CA2595958A1 (en) | 2006-08-03 |
| ZA200707315B (en) | 2008-11-26 |
| KR20070104893A (ko) | 2007-10-29 |
| EA200701582A1 (ru) | 2008-02-28 |
| EP1845991A2 (en) | 2007-10-24 |
| CN101111250A (zh) | 2008-01-23 |
| AU2006208621A1 (en) | 2006-08-03 |
| MX2007008397A (es) | 2007-09-07 |
| NZ556448A (en) | 2010-12-24 |
| PE20061042A1 (es) | 2006-11-20 |
| WO2006079556A3 (en) | 2006-09-21 |
| UY29352A1 (es) | 2006-08-31 |
| WO2006079556A2 (en) | 2006-08-03 |
| TW200637556A (en) | 2006-11-01 |
| AU2006208621B2 (en) | 2011-08-11 |
| BRPI0607108A2 (pt) | 2010-03-09 |
| IL184375A0 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073138A1 (es) | Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| ES2531660T3 (es) | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| DOP2007000079A (es) | Compuestos fenil amido heterocíclicos condensados | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
| CU20090209A7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| EA201170607A1 (ru) | Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости | |
| ECSP099319A (es) | Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus | |
| AR054475A1 (es) | Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion | |
| AR043875A1 (es) | Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |